share_log

科濟藥業-B:自願公告 - CT071已獲得FDA的IND批准用於治療復發/難治多發性骨髓瘤或復發/難治原發性漿細胞白血病

CARSGEN-B: VOLUNTARY ANNOUNCEMENT - CT071 RECEIVED IND CLEARANCE FROM THE FDA FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OR RELAPSED/REFRACTORY PRIMARY PLASMA CELL LEUKEMIA

香港交易所 ·  Dec 3, 2023 19:01
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more